Date: 2016-07-19
Type of information: Series A financing round
Company: Precision Ocular (UK)
Investors: Imperial Innovations (UK) Consort Medical (UK) NeoMed (Switzerland) V?Bio Ventures (Belgium) Hovione Scientia (Portugal)
Amount: £15.5 million
Funding type: series A financing round
Planned used: Founded in 2014, Precision Ocular is developing novel retinal treatments engineered to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The unique approach aims to increase therapeutic effectiveness, reduce side-effects and minimise frequency of treatments. Precision’s product development pipeline includes treatments for both prevalent retinal diseases, such as age related macular degeneration and diabetic macular oedema, as well as rare and orphan indications The funds will be used to develop programmes to treat retinal diseases such as age related macular degeneration and diabetic macular oedema, as well as rare and orphan indications. The funds will also enable the development of next generation ocular drug delivery systems which can administer cell and gene therapies to the back-of-eye.
Others: * On July 19, 2016, Precision Ocular, the Oxford-based retinal therapeutics company, announced that V-Bio Ventures joins the Company’s successful Series A financing round. In all, Precision Ocular has raised £15.5 million from investors Imperial Innovations, Consort Medical plc, NeoMed, V?Bio Ventures, and Hovione Scientia Ltd.
Therapeutic area: Ophtalmological diseases
